After Care Care Givers Governments Innovation Lifestyle and Mind Medical Specialties News NHS Oncology Pharma & Biotechnology

Coronavirus: Prostate-cancer men swap chemo for precision drugs

Men with advanced prostate cancer can take highly targeted hormone therapies at home instead of coming into hospital for chemotherapy, NHS England says.

Experts say it will relieve pressure on the NHS, which wants all urgent and essential cancer treatments to continue during the coronavirus pandemic.

The drugs are also smarter, kinder treatments and could extend the lives of many more patients, they say.

This precision-medicine approach is already used to treat other cancers.

Diagnosed with advanced prostate cancer in February, Stuart Fraser, 66, from Ashtead, in Surrey, will now take four enzalutamide tablets a day.

“Being diagnosed was a huge shock,” he said.

“What made it even more worrying was that, because of coronavirus, I was told I couldn’t have the usual treatment of chemotherapy, which would have affected my immune system.

“When I heard about other possible treatments like abiraterone and enzalutamide, I launched a petition to try to make sure men like me could get hold of it.

“That’s why it’s such great news that now no-one will be in the same position I was at the beginning of all this.”

Enzalutamide blocks the effect of the testosterone hormone on prostate-cancer cells, preventing them from growing.

Patients intolerant to enzalutamide, will be given abiraterone, which stops the body producing testosterone.

Until now, in England and Wales, the drugs were available only to patients for whom other hormone therapy had stopped working, although abiraterone was recommended in Scotland as a first-line treatment earlier this year.

Now, doctors can prescribe them when a patient is first diagnosed.

Read More

Meeta Ramnani
Meeta Ramnani
Meeta develops credible content about various markets based on deep research, opinions from experts and inputs from industry leaders. As the managing editor at Smart Industry News, she assures that every piece of news and article adds to the knowledge of decision makers. An avid bike rider, Meeta, is a postgraduate from Indian Institute of Journalism and New Media (IIJNM) Bangalore, where her specialization was Business Journalism. She carries experience from mainstream print media including The Times Group and Sakal Media Group.